|
Summary Company Profile |
State of Formation: State of Delaware
Year of Formation: 2018/2022
Residency (HQ): New Jersey (proposed)
Year of Inception: 2022 (proposed -follow us)
The full fledged operation should start off upon making manifest the
Market Participation essential as be continually listed under the Market
Participation Planning.
Investment Fund: CCECT-PT
Capital Investment Fund (proposed)
Investors
Participation: Only By Offering Memorandum
Investment Fund Manager: N/A
Investment Documents Printing: Okumaye Publishing Co, Inc
Venture
Background:
Website:
https://qualprean.enhknow (under
construction)
Company Business:
The production, marketing and sales of Diagnostic 3D Image Processing
Appliances and 2D Diagnostic Scan- and Prognostic Computed- Images.
Company Industry:
Medical Industry with special focus on
disease growth dynamics in human body.
Production Technology: Adoption Software:
BioMedic Computations Platform:
Diseases Prognostics Analytics
Enabler Technologies:
BioSynthesis
Reaction-Sequence Computations
(All technology is licensed through EnhKnow Adoption Brokerage)
Management Contact: Opubo G Benebo,
Executive Chairman,
email:
opubob@enhknow.com
|
About Venture:
A Computational prognostics
Oncology venture, Qualprean, [Inc] is an adopter venture that is
vested with the technology for performing Oncological
computations evaluating the growth and recession of cancers.
Qualprean,
[Inc] is an Adopter
Venture and accordingly is planned to be made into a public
company, and is in fact in the process of becoming a public
company. March
30, 2022
Redesigning the oncology services into Products Generations, the company
has designed three product-lines:
- 3D Image Processing Computer
Appliance
- Diagnostic 2D Image Scanner
Appliance
- 2D Image Computed-Prognostics
|
|
|
Market
Participation Planning |
|
Products: Prognostics Analytics |
|
>> Cancer Image Processing: |
|
>> Prognostics Computations |
|
>> Computed Image processing |
|
>>
Cancer
Biosynthesis & Growth |
|
|
Production Technology
|
Jan 1, 2021
The Base Technology enabling minimal working production operations
has at this time been consigned to EnhKnow for licensing to this firm
(Qualprean, Inc) which should position the firm to enter the Startup
Stage. Built on the Viability Analytics production
Digital Process
Factory with augmenting substitutions, the Base Technology is robust
and well-tested; yet it is expected to continue to still be tested
and improved while in use.
|
|
Present Developments |
February 16, 2024
Qualprean Prepares to File Reg A
Qualprean, Inc is now being
organized for Reg A Filing in the first step towards becoming a
Public Company. Accordingly the Production Technology, which
embodies the Cancer Chemical Environment and Cancer Gene Morphology
software, is being subjected to extensive testing even as these
software are being used for the purposes as explained. |
March 11, 2024
Chemical Metabolic Reactions Kinetics
For the computation of the Cancer
Prognosis, the cancer growth rate expressions are due to be supplied
by Biosynthesis Computing Center in centralization of the Computing
Technology, and as noteworthy mark of further progress, the IT
Platform enabling the evaluation of reactions postulates and the
rate expressions are being tested as part of the preparation for the
Reg A Filing, |
|
|
